Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance

Journal of Infection and Chemotherapy

Volumn 19, Issue 2, 2013, Pages 223-232

  Kashiwagi, Seizaburo ^a   Yoshida, Sanae ^b   Yamaguchi, Hiroki ^b   Mitsui, Noriko ^b   Tanigawa, Masatoshi ^b   Shiosakai, Kazuhito ^b   Yamanouchi, Naoki ^b   Shiozawa, Tomoo ^b   Yamaguchi, Fumie ^b  

^a Hakata Station Area Business Center   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Efficacy; Laninamivir; Long acting neuraminidase inhibitor; Postmarketing surveillance

Indexed keywords

LANINAMIVIR OCTANOATE;

ADULT; AGED; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; FEMALE; FEVER; HUMAN; INFLUENZA A; INFLUENZA B; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84880698280     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0481-9     Document Type: Article

References (16)

1. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53:186-92.
2. Kubo S, Tomozawa T, Kakuta M, Kakuta M, Tokumitsu A, Yanashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010;54:1256-64.
3. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza virus. Nature. 2009;460:1021-5.
4. Kiso M, Kubo S, Ozawa M, Mal Le Q, Nidom CA, Yamashita M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010;6:e1000786.
5. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575-82.
6. Watanabe A, Chang S-C, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51:1167-75.
7. Koyama K, Takahashi M, Oitate M, Naoki N, Takakusa H, Miura S, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009;53:4845-51.
8. Yamashita M. Development of anti-influenza agent (2). Antibiot Chemother. 2005;21:1767-73.
9. Analysis of clinical isolates of influenza in 2010/2011 seasons. 2011;32:317-323. http://www.kenko-nippon21forum.gr.jp/free/prerelease/ contents031.pdf. Accessed 1 Oct 2012
10. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.
11. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-42.
12. 50) of four neuraminidase inhibitors; oseltamivir, zanamivir, laninamivir, and peramivir to neuraminidase of influenza viruses isolated in the 2010/2011 influenza season in Japan. J Infect Chemother. doi: 10.1007/s10156-012-0377-8.
13. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kawashima T, Tanaka O, et al. Analysis of influenza in the winter 2004/2005. Focusing on the comparison between type A and type B. Nihon Iji Shinpo. 2005;4252:21-7.
14. Kawai N, Iwaki N, Maeda T, Kawashima T, Kanazawa H, Miyachi K, et al. Analysis of influenza in the winter 2004/2005. Comparison between type A and type B with respect to fever and efficacy. Influenza. 2006;7:41-6.
15. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis. 2006;43:439-44.
16. Kishida N, Takashita M, Fujisaki S, Itoh R, Doi T, Ejima M, et al. Infectious agents surveillance report -for the better drug compliance. 2010. http://idsc.nih.go.jp/iasr/32/381/dj3811.html. Accessed 1 Oct 2012